{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:03:39Z","timestamp":1791515019688,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen kanker","doi-asserted-by":"crossref","award":["KOTK_VUB\/2022\/13033"],"award-info":[{"award-number":["KOTK_VUB\/2022\/13033"]}],"id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006282","name":"Koning Boudewijnstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FWO Vlaanderen","award":["FWOSB110"],"award-info":[{"award-number":["FWOSB110"]}]},{"name":"FWO Vlaanderen","award":["FWOTM969"],"award-info":[{"award-number":["FWOTM969"]}]},{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013845","name":"Stichting tegen kanker","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013845","id-type":"DOI","asserted-by":"crossref"}]},{"name":"VIB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01629-3","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T12:19:50Z","timestamp":1730981990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages"],"prefix":"10.1186","volume":"17","author":[{"given":"Emma","family":"Verheye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daliya","family":"Kancheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Satilmis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vandewalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline M. R.","family":"Bardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile J.","family":"Clappaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Verstaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"De Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"De Veirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damya","family":"Laoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"1629_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, et al. Multiple myeloma. Nat Rev Dis Primer. 2017;3:1\u201320.","journal-title":"Nat Rev Dis Primer"},{"key":"1629_CR2","doi-asserted-by":"publisher","first-page":"102272","DOI":"10.1016\/j.eclinm.2023.102272","volume":"65","author":"GR Mohyuddin","year":"2023","unstructured":"Mohyuddin GR, Chakraborty R, Cliff ERS, Derman BA. Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. eClinicalMedicine. 2023;65:102272.","journal-title":"eClinicalMedicine"},{"key":"1629_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-023-00969-6","volume":"14","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024;14:1\u201313.","journal-title":"Blood Cancer J"},{"key":"1629_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41417-023-00712-0","volume":"31","author":"Q Wang","year":"2024","unstructured":"Wang Q, et al. An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer Gene Ther. 2024;31:420\u20136.","journal-title":"Cancer Gene Ther"},{"key":"1629_CR5","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","volume":"41","author":"M Dang","year":"2023","unstructured":"Dang M, et al. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell. 2023;41:1032-1047.e4.","journal-title":"Cancer Cell"},{"key":"1629_CR6","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","volume":"12","author":"SM Tirier","year":"2021","unstructured":"Tirier SM, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021;12:6960.","journal-title":"Nat Commun"},{"key":"1629_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij O, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1:493\u2013506.","journal-title":"Nat Cancer"},{"key":"1629_CR8","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1182\/bloodadvances.2022007217","volume":"6","author":"C Schinke","year":"2022","unstructured":"Schinke C, et al. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022;6:5873.","journal-title":"Blood Adv"},{"key":"1629_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41590-024-01808-x","volume":"25","author":"MME de Jong","year":"2024","unstructured":"de Jong MME, et al. An IL-1\u03b2-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma. Nat Immunol. 2024;25:820\u201333.","journal-title":"Nat Immunol"},{"key":"1629_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41525-022-00340-x","volume":"8","author":"W Pilcher","year":"2023","unstructured":"Pilcher W, et al. Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma. Npj Genomic Med. 2023;8:1\u201318.","journal-title":"Npj Genomic Med"},{"key":"1629_CR11","first-page":"351","volume":"1","author":"K Asosingh","year":"2000","unstructured":"Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J Off J Eur Haematol Assoc. 2000;1:351\u20136.","journal-title":"Hematol J Off J Eur Haematol Assoc"},{"key":"1629_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1034\/j.1600-065X.2003.00035.x","volume":"194","author":"K Vanderkerken","year":"2003","unstructured":"Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003;194:196\u2013206.","journal-title":"Immunol Rev"},{"key":"1629_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/bjc.1997.409","volume":"76","author":"K Vanderkerken","year":"1997","unstructured":"Vanderkerken K, et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL\/KaLwRij mouse. Br J Cancer. 1997;76:451\u201360.","journal-title":"Br J Cancer"},{"key":"1629_CR14","doi-asserted-by":"publisher","first-page":"e005319","DOI":"10.1136\/jitc-2022-005319","volume":"11","author":"R Fan","year":"2023","unstructured":"Fan R, et al. Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma. J Immunother Cancer. 2023;11:e005319.","journal-title":"J Immunother Cancer"},{"key":"1629_CR15","first-page":"2122","volume":"5","author":"ATL Lun","year":"2016","unstructured":"Lun ATL, McCarthy DJ, Marioni JC. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Research. 2016;5:2122.","journal-title":"F1000Research"},{"key":"1629_CR16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/s41590-020-0736-z","volume":"21","author":"X Xie","year":"2020","unstructured":"Xie X, et al. Single-cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection. Nat Immunol. 2020;21:1119\u201333.","journal-title":"Nat Immunol"},{"key":"1629_CR17","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.ccell.2022.10.008","volume":"40","author":"S Salcher","year":"2022","unstructured":"Salcher S, et al. High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer. Cancer Cell. 2022;40:1503-1520.e8.","journal-title":"Cancer Cell"},{"key":"1629_CR18","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","volume":"8","author":"RS Firestone","year":"2024","unstructured":"Firestone RS, et al. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -na\u00efve multiple myeloma. Blood Adv. 2024;8:1600\u201311.","journal-title":"Blood Adv"},{"key":"1629_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cellimm.2018.02.009","volume":"327","author":"X Zhang","year":"2018","unstructured":"Zhang X, et al. Characterization of CD4+ T cell-mediated cytotoxicity in patients with multiple myeloma. Cell Immunol. 2018;327:62\u20137.","journal-title":"Cell Immunol"},{"key":"1629_CR20","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1038\/s41467-021-23324-4","volume":"12","author":"M Andreatta","year":"2021","unstructured":"Andreatta M, et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat Commun. 2021;12:2965.","journal-title":"Nat Commun"},{"issue":"1","key":"1629_CR21","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.xcrm.2022.100868","volume":"4","author":"S Bukhari","year":"2023","unstructured":"Bukhari S, Henick BS, Winchester RJ, Lerrer S, Adam K, Gartshteyn Y, Maniar R, Lin Z, Khodadadi-Jamayran A, Tsirigos A, Salvatore MM, Lagos GG, Reiner SL, Dallos MC, Mathew M, Rizvi NA, Mor A. Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Rep Med. 2023;4(1):868. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100868.","journal-title":"Cell Rep Med."},{"key":"1629_CR22","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/leu.2012.113","volume":"26","author":"E Van Valckenborgh","year":"2012","unstructured":"Van Valckenborgh E, et al. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia. 2012;26:2424\u20138.","journal-title":"Leukemia"},{"key":"1629_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2326-6066.CIR-20-0431","volume":"9","author":"M Kiss","year":"2021","unstructured":"Kiss M, et al. IL1\u03b2 promotes immune suppression in the tumor microenvironment independent of the inflammasome and gasdermin D. Cancer Immunol Res. 2021;9:309\u201323.","journal-title":"Cancer Immunol Res"},{"key":"1629_CR24","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.immuni.2023.07.001","volume":"56","author":"Z Liu","year":"2023","unstructured":"Liu Z, et al. Dendritic cell type 3 arises from Ly6C+ monocyte-dendritic cell progenitors. Immunity. 2023;56:1761-1777.e6.","journal-title":"Immunity"},{"key":"1629_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","volume":"580","author":"B Maier","year":"2020","unstructured":"Maier B, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020;580:257\u201362.","journal-title":"Nature"},{"key":"1629_CR26","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms23020904","volume":"23","author":"E Verheye","year":"2022","unstructured":"Verheye E, et al. Dendritic cell-based immunotherapy in multiple myeloma: challenges, opportunities, and future directions. Int J Mol Sci. 2022;23:904.","journal-title":"Int J Mol Sci"},{"key":"1629_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s12276-024-01192-4","volume":"56","author":"DAG Barisas","year":"2024","unstructured":"Barisas DAG, Choi K. Extramedullary hematopoiesis in cancer. Exp Mol Med. 2024;56:549\u201358.","journal-title":"Exp Mol Med"},{"key":"1629_CR28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/30996","volume":"393","author":"SR Bennett","year":"1998","unstructured":"Bennett SR, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478\u201380.","journal-title":"Nature"},{"key":"1629_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/31002","volume":"393","author":"SP Schoenberger","year":"1998","unstructured":"Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480\u20133.","journal-title":"Nature"},{"key":"1629_CR30","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1158\/0008-5472.CAN-22-0094","volume":"82","author":"A Murgaski","year":"2022","unstructured":"Murgaski A, et al. Efficacy of CD40 agonists is mediated by distinct cDC subsets and subverted by suppressive macrophages. Cancer Res. 2022;82:3785\u2013801.","journal-title":"Cancer Res"},{"key":"1629_CR31","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fimmu.2012.00274","volume":"3","author":"SV Schmidt","year":"2012","unstructured":"Schmidt SV, Nino-Castro AC, Schultze JL. Regulatory dendritic cells: there is more than just immune activation. Front Immunol. 2012;3:274.","journal-title":"Front Immunol"},{"key":"1629_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-024-01818-6","volume":"10","author":"L Xu","year":"2024","unstructured":"Xu L, et al. Targeted immunotherapy: harnessing the immune system to battle multiple myeloma. Cell Death Discov. 2024;10:1\u201317.","journal-title":"Cell Death Discov"},{"key":"1629_CR33","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/s41467-021-26598-w","volume":"12","author":"DC Croucher","year":"2021","unstructured":"Croucher DC, et al. Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression. Nat Commun. 2021;12:6322.","journal-title":"Nat Commun"},{"key":"1629_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-014-0043-z","volume":"3","author":"W Jing","year":"2015","unstructured":"Jing W, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer. 2015;3:2.","journal-title":"J Immunother Cancer"},{"key":"1629_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127807","author":"JK Bailur","year":"2019","unstructured":"Bailur JK, et al. Early alterations in stem-like\/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy. JCI Insight. 2019. https:\/\/doi.org\/10.1172\/jci.insight.127807.","journal-title":"JCI Insight"},{"key":"1629_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-021-00440-4","volume":"11","author":"A Visram","year":"2021","unstructured":"Visram A, Dasari S, Anderson E, Kumar S, Kourelis TV. Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. Blood Cancer J. 2021;11:45.","journal-title":"Blood Cancer J"},{"key":"1629_CR37","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","volume":"22","author":"MME de Jong","year":"2021","unstructured":"de Jong MME, et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat Immunol. 2021;22:769\u201380.","journal-title":"Nat Immunol"},{"key":"1629_CR38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","volume":"29","author":"M Larrayoz","year":"2023","unstructured":"Larrayoz M, et al. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nat Med. 2023;29:632\u201345.","journal-title":"Nat Med"},{"key":"1629_CR39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser C, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9:116.","journal-title":"J Hematol Oncol"},{"key":"1629_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","volume":"12","author":"Z Liu","year":"2023","unstructured":"Liu Z, et al. Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol. 2023;12:99.","journal-title":"Exp Hematol Oncol"},{"key":"1629_CR41","doi-asserted-by":"publisher","first-page":"10532","DOI":"10.18632\/oncotarget.3300","volume":"6","author":"K De Veirman","year":"2015","unstructured":"De Veirman K, et al. Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells. Oncotarget. 2015;6:10532\u201347.","journal-title":"Oncotarget"},{"key":"1629_CR42","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","volume":"186","author":"J Gungabeesoon","year":"2023","unstructured":"Gungabeesoon J, et al. A neutrophil response linked to tumor control in immunotherapy. Cell. 2023;186:1448-1464.e20.","journal-title":"Cell"},{"key":"1629_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41416-018-0352-y","volume":"120","author":"H Ma","year":"2019","unstructured":"Ma H, et al. Interferon-alpha promotes immunosuppression through IFNAR1\/STAT1 signalling in head and neck squamous cell carcinoma. Br J Cancer. 2019;120:317\u201330.","journal-title":"Br J Cancer"},{"key":"1629_CR44","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3390\/diagnostics11040702","volume":"11","author":"J Szpor","year":"2021","unstructured":"Szpor J, et al. Dendritic cells are associated with prognosis and survival in breast cancer. Diagnostics. 2021;11:702.","journal-title":"Diagnostics"},{"key":"1629_CR45","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","volume":"50","author":"R Zilionis","year":"2019","unstructured":"Zilionis R, et al. Single cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019;50:1317-1334.e10.","journal-title":"Immunity"},{"key":"1629_CR46","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1111\/cas.15800","volume":"114","author":"J Jiang","year":"2023","unstructured":"Jiang J, et al. Distinct mechanisms of dysfunctional antigen-presenting DCs and monocytes by single-cell sequencing in multiple myeloma. Cancer Sci. 2023;114:2750\u201360.","journal-title":"Cancer Sci"},{"key":"1629_CR47","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.3390\/cancers14081976","volume":"14","author":"Y Saito","year":"2022","unstructured":"Saito Y, Komori S, Kotani T, Murata Y, Matozaki T. The role of type-2 conventional dendritic cells in the regulation of tumor immunity. Cancers. 2022;14:1976.","journal-title":"Cancers"},{"key":"1629_CR48","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","volume":"26","author":"N Alrasheed","year":"2020","unstructured":"Alrasheed N, et al. Marrow-infiltrating regulatory T cells correlate with the presence of dysfunctional CD4+PD-1+ cells and inferior survival in patients with newly diagnosed multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26:3443\u201354.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1629_CR49","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1084\/jem.20171440","volume":"215","author":"S Hoves","year":"2018","unstructured":"Hoves S, et al. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J Exp Med. 2018;215:859\u201376.","journal-title":"J Exp Med"},{"key":"1629_CR50","doi-asserted-by":"publisher","unstructured":"Maltez V, et al. Agonistic anti-CD40 converts Tregs into Type 1 effectors within the tumor micro-environment. Preprint at https:\/\/doi.org\/10.1101\/2022.10.17.512537. 2022.","DOI":"10.1101\/2022.10.17.512537"},{"key":"1629_CR51","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1046\/j.1365-2141.2003.04322.x","volume":"121","author":"T Hayashi","year":"2003","unstructured":"Hayashi T, et al. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol. 2003;121:592\u20136.","journal-title":"Br J Haematol"},{"key":"1629_CR52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3324\/haematol.2009.008003","volume":"95","author":"M Hussein","year":"2010","unstructured":"Hussein M, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010;95:845\u20138.","journal-title":"Haematologica"},{"key":"1629_CR53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/07357907.2014.988340","volume":"33","author":"C Qi","year":"2015","unstructured":"Qi C, et al. Co-expression of CD40\/CD40L on XG1 multiple myeloma cells promotes IL-6 autocrine function. Cancer Invest. 2015;33:6\u201315.","journal-title":"Cancer Invest"},{"key":"1629_CR54","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3390\/cancers13061302","volume":"13","author":"D Djureinovic","year":"2021","unstructured":"Djureinovic D, Wang M, Kluger HM. Agonistic CD40 antibodies in cancer treatment. Cancers. 2021;13:1302.","journal-title":"Cancers"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01629-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01629-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01629-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T18:14:04Z","timestamp":1732990444000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01629-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1629"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01629-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mice: All experimental procedures, follow-up and housing complied with the guidelines of the Belgian Council for Laboratory Animal Science and were approved by the Ethical Committee for Animal Experiments of the Vrije Universiteit Brussel (LA1230281, CEP 19-281-3, CEP 20-281-5, CEP 23-281-5, CEP 23-281-6, CEP 23-281-14). Human samples: This study was conducted in compliance with the Declaration of Helsinki and received approval from the University Hospital of Brussels (B.U.N. 143201838414). All patients provided informed consent after the nature and possible consequences of the study had been explained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}